Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF + 3TC + ANV effects on cardiovascular risk and gut microbiota in HIV-1 patients with dyslipidemia
ChiCTR2500098499Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate, lamivudine and ainuovirine in human immunodeficiency virus infection (HIV) and dyslipidemia, sponsored by First Hospital of China Medical University. Primary endpoint: Cardiovascular disease risk score. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tenofovir disoproxil fumaratelamivudineainuovirine
03
Conditions
human immunodeficiency virus infection (HIV)dyslipidemia
Beyond the preview
Go deeper on ChiCTR2500098499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098499.